Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

PolyTherics enters into research collaboration agreement Celtic Pharma

PolyTherics : 27 February, 2008  (New Product)
PolyTherics, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy, has entered into a broad research collaboration agreement with Celtic Pharma Development Services Bermuda, a subsidiary of Celtic Pharmaceutical, a global private equity investment fund focused on the biopharma industry.
Under the terms of the agreement, PolyTherics’ proprietary drug modification technologies will be used to enhance certain of the innovative pharmaceutical products being developed by Celtic Pharma.

The parties plan jointly to develop and validate modifications of drugs submitted to the collaboration by Celtic Pharma, in order to improve their performance and assess their future development potential.

PolyTherics has substantial expertise in the targeted and selective modification of compounds for therapeutic and diagnostic application.

Through the application of a platform of polymer-based technologies, it is developing compounds as drug candidates in both existing and emerging markets. With the growing commercial impact of biopharmaceutical products, and particularly next generation antibody fragments, PolyTherics is strongly positioned to address these opportunities.

PolyTherics has revenue-generating research and development contracts in place with several companies and is in discussion with a number of others.

Dr Keith Powell, chief executive officer of PolyTherics, said: “We view collaboration through partnership as fundamental to exemplifying the development potential of our proprietary technologies and fulfilling our strategy. The opportunity to collaborate with a high calibre, product-focused company such as Celtic Pharma is a significant milestone in the development of PolyTherics, and we are delighted to be working with Celtic Pharma on several of the products in their portfolio. We believe that our work together will show that PolyTherics’ proprietary technologies can be used to improve pharmaceutical products to increase their commercial value.”

Celtic Pharma currently has a portfolio of nine novel pharmaceutical products in clinical development across a range of therapeutic areas. Each product is being developed to address important unmet medical needs, and Celtic Pharma aims to move these products rapidly and effectively through clinical development to regulatory approval.

Dr Bill Henry, managing director - Global Head of CMC at Celtic Pharma, said: “We are excited about accessing the technology capability of PolyTherics through collaboration and exploring its potential impact on our product pipeline.”

Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo